Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ONO PHARMACEUTICAL : Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) (94.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/04/2012 | 04:15am CEST

June 4th, 2012

ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

Bristol-Myers Squibb Company (hereinafter referred to as "BMS") announced the results from Phase 1 study in patients with non-small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC) to be published in New England Journal of Medicine (NEJM) and presented at 48th

Annual Meeting of the American Society of Clinical Oncology (ASCO), on June 2nd (US time).

ONO-4538/BMS-936558, a fully human anti-PD-1 antibody, is an investigational cancer immunotherapy generated under a research collaboration entered into in May 2005 between Ono Pharmaceutical Co., Ltd. (hereinafter referred to as "Ono") and Medarex, Inc. When Medarex, Inc. was acquired by BMS in

2009, it also granted BMS its rights to develop and commercialize the anti-PD-1 antibody in North America. Through the collaboration agreement entered into in September 2011 between Ono and BMS, Ono granted BMS exclusive rights to develop and commercialize ONO-4538/BMS-936558 in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize the compound.

BMS is conducting a Phase 2 study in RCC in North America and Europe, and plans to initiate registrational studies for anti-PD-1 this year in NSCLC and RCC, and late 2012, early 2013 for metastatic melanoma. On the other hand, Ono is conducting a Phase 2 study in metastatic melanoma in Japan, and plans to initiate clinical studies in RCC and NSCLC, taking account of the development status in United States and Europe.

Attached from the following page is the press release made by BMS for your information.

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1

Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
05/25 ONO PHARMACEUTICAL : U.S. Food and Drug Administration Accepts for Priority Revi..
05/18 ONO PHARMACEUTICAL : Receives Supplemental Manufacturing and Marketing Approval ..
05/12 ONO PHARMACEUTICAL : Seikagaku and Ono Reach a Basic Agreement Related to Co-dev..
05/11 ONO PHARMACEUTICAL : Notice regarding Differences between Non-consolidated Resul..
05/08 ONO PHARMACEUTICAL : European Commission Approves Bristol-Myers Squibb’s O..
04/24 ONO PHARMACEUTICAL : Opdivo® (nivolumab) Designated for the Treatment of Biliary..
04/24 ONO PHARMACEUTICAL : Bristol-Myers Squibb Receives Positive CHMP Opinion Recomme..
04/06 ONO PHARMACEUTICAL : Numab and Ono Pharmaceutical Co., Ltd. Enter into a Researc..
04/06 ONO PHARMACEUTICAL : U.S. Food and Drug Administration Accepts for Priority Revi..
04/05 ONO PHARMACEUTICAL : Five-Year Survival Observed With Opdivo (nivolumab) in Pati..
More news
Sector news : Generic Pharmaceuticals
05/29 WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
05/29DJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
05/10 BRISTOL-MYERS SQUIBB : A Deep Dive Finds Some Pearls
01/23 Bristol Catches A Break At Last
2016 Opdivo's price halved in Japan
2016 Bristol's Bid To Get Ahead In Head And Neck
2016 A European Biotech Stock Basket For 2016 - Update
Advertisement
Financials ( JPY)
Sales 2018 249 605 M
EBIT 2018 -
Net income 2018 44 220 M
Finance 2018 143 944 M
Yield 2018 1,92%
P/E ratio 2018 28,77
P/E ratio 2019 24,46
EV / Sales 2018 4,96x
EV / Sales 2019 4,53x
Capitalization 1 381 762 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 2 715  JPY
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-8.34%12 457
OTSUKA HOLDINGS CO LTD-1.14%25 320
SUN PHARMACEUTICAL IND..-10.03%18 653
SHANGHAI FOSUN PHARMAC..34.10%10 967
ASPEN PHARMACARE HOLDI..3.19%10 281
CADILA HEALTHCARE LTD25.37%7 218
More Results